Cookies on this site

Research Projects Available

Dphil in cardiovascular science

Technology, Artificial Intelligence, and Data Driven Solutions for Cardiovascular and Metabolic Disease

DPhil in medical sciences opportunities will appear below:

MSc by Research in medical sciences opportunities will appear below:

Betty Raman

MBBS DPhil FESC FRACP


Associate Professor of Cardiovascular Medicine

  • NIHR South Central RRDN Cardiology Specialty Lead
  • Hon. Consultant Cardiologist (Loc)
  • Oxford Programme Director of BHF Doctoral Training Programme on Technology, Data and AI (Imperial-Oxford DTP)
  • Wellcome Career Development Award Fellow
  • RDM Cardiovascular Medicine EDI Champion

Prof Betty Raman is a senior honorary consultant cardiologist specialising in advanced cardiovascular imaging (CMR and cardiac CT) and inherited and cardiomyopathic heart disease. She leads a translational research programme in monogenic (e.g., HCM, DCM etc) and polygenic cardiac (hypertensive heart diseases, cardiometabolic etc.) diseases that bridge mechanistic discovery, clinical application, and innovation in drug development.

After completing her specialist cardiology training in Australia (FRACP), she joined the University of Oxford in 2015 to pursue a DPhil in hypertrophic cardiomyopathy, the leading cause of sudden cardiac death in young adults and athletes. Her doctoral work led to the development of a novel oxygen sensitive magnetic resonance method that detects myocardial hypoxia non-invasively and holds promise as an early biomarker of disease activity. This pioneering work has been recognised internationally through awards from the ESC, AHA, BSCMR, SCMR, and BCS.

Building on this foundation, she was awarded a British Heart Foundation Transition Fellowship (2020) and subsequently a Wellcome Career Development Award (2024) to advance a multidisciplinary research programme integrating imaging, genetics, energetics, and computational modelling. Her goal is to identify and validate early markers of disease progression in hypertrophic (e.g., HCM) and related cardiomyopathies, enabling more precise risk prediction and supporting evaluation of emerging therapies.

During the COVID 19 pandemic, she led the C-MORE study, a large multicentre initiative that combined MRI, cardiopulmonary exercise testing, and cognitive assessments to characterise the long term multi organ consequences of COVID 19. This work helped shape understanding of post-viral cardiovascular and systemic recovery.

Her current research focuses on:

  1. Early stage disease detection and monitoring in cardiomyopathies using next generation CMR including BOLD, DTI, spectroscopy, and radiomics.

  2. Mechanistic biomarkers to support early phase and adaptive clinical trials.

  3. Cross organ interactions in cardiometabolic disease, integrating heart, brain, liver, and renal imaging.

As a senior academic leader, she collaborates widely across academia, the NHS, and industry to translate advanced imaging into clinical and commercial impact. She actively welcomes scientific collaborators, students, and industrial partners interested in biomarker discovery, imaging enabled trial design, and AI based modelling for cardiovascular disease.

Recent publications

Can Intravenous Cangrelor Protect the Myocardium in Infarction-related Cardiogenic Shock?

Journal article

Raman B. and Bohula EA., (2026), Circulation

Recombinant shingles vaccination and the risk of cardiovascular events.

Journal article

Corsi-Zuelli F. et al, (2026), Nat Med

Late Gadolinium Enhancement in Nonischemic Dilated Cardiomyopathy.

Journal article

Raman B. and Prasad SK., (2026), Circulation, 154, 512 - 516

HFpEF and MASLD: converging mechanisms and clinical implications.

Journal article

Capone F. et al, (2026), Nat Rev Cardiol, 23, 584 - 608

Cardiac morphology and flow dynamics in children born to hypertensive pregnancies.

Journal article

Sattwika PD. et al, (2026), Eur Heart J Imaging Methods Pract, 4

Pictorial review: a step-by-step guide to coronary CT angiography with photon-counting detector CT.

Journal article

Xie C. et al, (2026), Br J Radiol, 99, 1518 - 1528

Trientine for hypertrophic cardiomyopathy: a phase 2 trial.

Journal article

Farrant JP. et al, (2026), Eur Heart J

Non-invasive pressure-volume loop analysis in left ventricular load manipulation.

Journal article

Pola K. et al, (2026), Clin Physiol Funct Imaging, 46

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

Journal article

HCMR Investigators . et al, (2026), JAMA, 335, 1959 - 1969

Biobank-Scale Plasma Proteomics Identifies Novel Biomarkers in Hypertrophic Cardiomyopathy.

Journal article

Chan JH. et al, (2026), Circ Genom Precis Med, 19

Evaluating Acute Ischemic Myocardial Injury With Photon-Counting Computed Tomography.

Journal article

Kotronias RA. et al, (2026), JACC Cardiovasc Imaging, 19, 284 - 287

Comparison of cardiac diffusion MRI using multiple prospective respiratory motion correction techniques.

Journal article

Jermy S. et al, (2026), Magn Reson Med, 95, 442 - 456

Human genetics implicate thromboembolism in the pathogenesis of long COVID in individuals of European ancestry.

Journal article

Schuermans A. et al, (2025), Nat Cardiovasc Res, 4, 1662 - 1676

Computational modelling of myocardial metabolism in patients with advanced heart failure.

Journal article

Beyhoff N. et al, (2025), Eur J Heart Fail, 27, 3411 - 3422

Sleep apnea at the frontier- an integrated multidisciplinary functional framework.

Journal article

Beache GM. et al, (2025), Sleep Med Rev, 84

Subclinical Postpartum Renal Structure After Hypertensive Pregnancy Disorders.

Journal article

Cutler HR. et al, (2025), Hypertension, 82, 1948 - 1958

Sex Differences in the Genetic Causes of Dilated Cardiomyopathy.

Journal article

Mangino M. et al, (2025), J Am Coll Cardiol, 86, 400 - 403

Could CT radiomics be the new frontier for myocardial tissue characterization in cardiomyopathies?

Journal article

Raman B. and Clarke N., (2025), Eur Heart J Cardiovasc Imaging, 26, 1049 - 1050

Multiorgan Imaging for Interorgan Crosstalk in Cardiometabolic Diseases.

Journal article

Devesa A. et al, (2025), Circ Res, 136, 1454 - 1475

Considerations for drug trials in hypertrophic cardiomyopathy.

Journal article

Farrant JP. et al, (2025), ESC Heart Fail, 12, 1095 - 1112

Demographic-Based Personalized Left Ventricular Hypertrophy Thresholds for Hypertrophic Cardiomyopathy Diagnosis.

Journal article

Shiwani H. et al, (2025), J Am Coll Cardiol, 85, 685 - 695

Myocardial disarray and fibrosis across hypertrophic cardiomyopathy stages associate with ECG markers of arrhythmic risk.

Journal article

Ashkir Z. et al, (2025), Eur Heart J Cardiovasc Imaging, 26, 218 - 228

More publications